2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3092 Management and outcomes of cancer-associated lower extremity superficial vein thrombosis: A retrospective study

Mysa Saad, MD, Ranjeeta Mallick, PhD2, Cameron Brown3, Marc Carrier Jr, MD4, Tzu-Fei Wang, MD5
1 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, University of Ottawa, Ottawa, Ontario, Canada
2 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
4 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, University of Ottawa, Ottawa, Ontario, Canada
5 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, University of Ottawa, Ottawa, Ontario, Canada

Background: Patients with cancer are at increased risk of developing superficial vein thrombosis (SVT) compared to the general population. Although historically considered less clinically significant than deep vein thrombosis (DVT), SVT is associated with thrombus propagation, subsequent DVT and/or pulmonary embolism (PE), and venous thromboembolism (VTE)-related hospitalization. Furthermore, cancer-associated SVT has been associated with mortality comparable to that of cancer-associated DVT. Despite these risks, data on the management and outcomes of cancer-associated lower extremity SVT (LESVT) remain limited. Current treatment strategies are largely extrapolated from studies in the general population, as evidence-based recommendations regarding the optimal anticoagulant agent, dose, and duration in patients with cancer are lacking. Therefore, we aimed to evaluate the management and clinical outcomes of patients with cancer-associated LESVT treated at a tertiary care center.

Methods: This retrospective cohort study included adults diagnosed with cancer-associated LESVT at The Ottawa Hospital between June 1, 2019, and December 31, 2023. Patients with concomitant DVT or PE or those receiving therapeutic anticoagulation at the time of LESVT diagnosis were excluded. Clinical data were extracted from electronic medical records from one year before to one year after LESVT diagnosis. Collected variables included patient demographics, cancer characteristics, LESVT features, anticoagulation management, and clinical outcomes. The primary efficacy outcome was the 3-month cumulative incidence of recurrent VTE (defined as new or progressive SVT, DVT, or PE). The primary safety outcome was the 3-month incidence of major bleeding, defined according to the International Society on Thrombosis and Haemostasis criteria. Secondary outcomes included recurrent VTE, bleeding, hospitalization, and all-cause mortality at 6 and 12 months. Baseline characteristics and management strategies were summarized descriptively. Cumulative incidence accounting for the competing risk of death were used to evaluate recurrent VTE and bleeding outcomes.

Results: A total of 81 patients were included. The mean (SD) age was 64.7 (10.1) years, with 56.8% (N=46) being female. Hematologic malignancies were the most common cancer type (23.5%), followed by breast and genitourinary cancers (21% each). Among patients with solid tumors, more than half had metastatic disease. The greater saphenous vein was involved in 58% of the cases, and 41.5% of patients had SVT located within 3 cm of the deep vein junction. Overall, 75% (N=62) of patients received anticoagulation for the LESVT, most commonly a direct oral anticoagulant (N=55). Among anticoagulated patients, 56.5% received prophylactic-dose anticoagulation, while the remainder received therapeutic- or intermediate-dose anticoagulation. The median duration of anticoagulation was 6.8 months (IQR 1.5-11.9). The 3-month cumulative incidence of recurrent VTE was 16.5% (95% CI, 9.3-25.5). Recurrent events were evenly distributed between SVT and DVT/PE. The 3-month cumulative incidence of major bleeding was 2.5% (95% CI, 0.5-7.9), Rates of recurrent VTE and major bleeding appeared similar across those treated with therapeutic, prophylactic doses, or no anticoagulation. The cumulative incidence of all-cause mortality was 8.7% (95% CI, 3.8-16.2) at 3 months and 17.6% (95% CI, 10.1-26.7) at 12 months.

Conclusions: Cancer-associated LESVT is associated with substantial risks of recurrent VTE and mortality despite the majority being treated with anticoagulation, while the risk of major bleeding appears lower but remains clinically relevant.  Further prospective studies are needed to define the optimal management of cancer-associated LESVT.

Mysa Saad, MD: No relevant conflicts of interest to declare.